← Leaderboards
Tyler J. Curiel
Baylor Research Institute
$19,414,535
Attributed
$24,035,043
Total exposure
30
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$32,260,095 · 30
FDA$775,000 · 1
By mechanism
R01$19,599,877 · 11
P30$12,179,805 · 9
R21$1,000,075 · 3
P51$222,343 · 4
R13$23,450 · 1
M01$9,545 · 3
Top collaborators
- Rong Li7 shared
- Shai Shlomo Shen-Orr6 shared
- Weixing Wilson Zhao3 shared
- Yanfen Hu2 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCancer TherapyMemberImmuneProgramsBaseResearch PersonnelTumorTranslatingInsightMouse ModelFundingGrowthCellsSignal TransductionTumor ImmunityResponseImmunotherapyMeetingsClinical ResearchCancer CenterClinical TrialsMediatingNeoplastic Cell
Grant awards (102)
Adipocyte PD-L1 in the Breast Tumor Microenvironment$660,030
R01 · FY2025 · CA
Melanocyte PDL1 control of UVB-induced IFN-I$635,946
R01 · FY2025 · CA · contact PI
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments$633,409
R01 · FY2025 · CA · contact PI
Adipocyte PD-L1 in the Breast Tumor Microenvironment$675,405
R01 · FY2024 · CA
Melanocyte PDL1 control of UVB-induced IFN-I$635,946
R01 · FY2024 · CA · contact PI
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments$620,740
R01 · FY2023 · CA · contact PI
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments$646,659
R01 · FY2022 · CA · contact PI
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy$601,546
R01 · FY2022 · CA · contact PI
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy$565,310
R01 · FY2021 · CA · contact PI
Regulation of ER-beta Signaling in Carcinogenesis$484,266
R01 · FY2021 · CA
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy$209,793
R01 · FY2021 · CA · contact PI
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration$640,547
R01 · FY2020 · CA · contact PI
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy$623,486
R01 · FY2020 · CA · contact PI
Regulation of ER-beta Signaling in Carcinogenesis$491,400
R01 · FY2020 · CA
Advances in Cancer Immunotherapy Educational Program-San Antonio$23,450
R13 · FY2020 · CA · contact PI
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration$621,419
R01 · FY2019 · CA · contact PI
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy$530,090
R01 · FY2019 · CA · contact PI
Regulation of ER-beta Signaling in Carcinogenesis$511,684
R01 · FY2019 · CA
RC-2: Clinical Research Core (CRC)$88,103
P30 · FY2019 · AG · contact PI
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration$640,839
R01 · FY2018 · CA · contact PI
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy$582,917
R01 · FY2018 · CA · contact PI
Regulation of ER-beta Signaling in Carcinogenesis$479,568
R01 · FY2018 · CA
RC-2: Clinical Research Core (CRC)$88,103
P30 · FY2018 · AG · contact PI
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration$650,815
R01 · FY2017 · CA · contact PI
Regulation of ER-beta Signaling in Carcinogenesis$479,568
R01 · FY2017 · CA
RC-2: Clinical Research Core (CRC)$92,775
P30 · FY2017 · AG · contact PI
B7-H1 Signaling in Ovarian Cancer$310,213
R01 · FY2016 · CA · contact PI
RC-2: Clinical Research Core (CRC)$89,009
P30 · FY2016 · AG · contact PI
B7-H1 Signaling in Ovarian Cancer$310,213
R01 · FY2015 · CA · contact PI
RC-2: Clinical Research Core (CRC)$59,662
P30 · FY2015 · AG · contact PI
B7-H1 Signaling in Ovarian Cancer$300,907
R01 · FY2014 · CA · contact PI
B7-H1 Signaling in Ovarian Cancer$291,600
R01 · FY2013 · CA · contact PI
SENIOR LEADERSHIP$153,325
P30 · FY2013 · CA · contact PI
Immune aspects of mTOR inhibition for cancer prevention (PQ5)$152,826
R21 · FY2013 · CA · contact PI
SENIOR LEADERSHIP$75,000
P30 · FY2013 · CA · contact PI
CAREER DEVELOPMENT$28,501
P30 · FY2013 · CA · contact PI
DEVELOPMENTAL$25,389
P30 · FY2013 · CA · contact PI
CANCER PREVENTION AND POPULATION SCIENCES$23,133
P30 · FY2013 · CA · contact PI
ANTIBODY$19,493
P30 · FY2013 · CA · contact PI
ADMINISTRATION$15,949
P30 · FY2013 · CA · contact PI
PLANNING AND EVALUATION$5,677
P30 · FY2013 · CA · contact PI
B7-H1 Signaling in Ovarian Cancer$310,040
R01 · FY2012 · CA · contact PI
Immune aspects of mTOR inhibition for cancer prevention (PQ5)$195,098
R21 · FY2012 · CA · contact PI
SENIOR LEADERSHIP$289,125
P30 · FY2011 · CA · contact PI
DEVELOPMENTAL$262,892
P30 · FY2011 · CA · contact PI
ADMINISTRATION$112,153
P30 · FY2011 · CA · contact PI
CANCER PREVENTION AND POPULATION SCIENCES$42,241
P30 · FY2011 · CA · contact PI
CAREER DEVELOPMENT$39,961
P30 · FY2011 · CA · contact PI
ANTIBODY$26,951
P30 · FY2011 · CA · contact PI
PLANNING AND EVALUATION$21,908
P30 · FY2011 · CA · contact PI
SENIOR LEADERSHIP$294,616
P30 · FY2010 · CA · contact PI
A Novel MAPK family in T. gondii$268,893
R01 · FY2010 · AI · contact PI
DEVELOPMENTAL$262,987
P30 · FY2010 · CA · contact PI
ADMINISTRATION$112,197
P30 · FY2010 · CA · contact PI
PHASE II TRIAL OF ONTAK TO TREAT OVARIAN CANCER UNDER B*$75,000
R01 · FY2010 · FD · contact PI
CANCER PREVENTION AND POPULATION SCIENCES$43,524
P30 · FY2010 · CA · contact PI
CAREER DEVELOPMENT$40,608
P30 · FY2010 · CA · contact PI
ANTIBODY$26,957
P30 · FY2010 · CA · contact PI
PLANNING AND EVALUATION$21,916
P30 · FY2010 · CA · contact PI
SENIOR LEADERSHIP$300,207
P30 · FY2009 · CA · contact PI
Plasmacytoid dendritic cell behavior in ovarian cancer$273,408
R01 · FY2009 · CA · contact PI
A Novel MAPK family in T. gondii$271,608
R01 · FY2009 · AI · contact PI
DEVELOPMENTAL$267,688
P30 · FY2009 · CA · contact PI
ADMINISTRATION$114,202
P30 · FY2009 · CA · contact PI
CANCER PREVENTION AND POPULATION SCIENCES$44,382
P30 · FY2009 · CA · contact PI
CAREER DEVELOPMENT$41,373
P30 · FY2009 · CA · contact PI
ANTIBODY$27,438
P30 · FY2009 · CA · contact PI
PLANNING AND EVALUATION$22,308
P30 · FY2009 · CA · contact PI
Plasmacytoid dendritic cell behavior in ovarian cancer$273,408
R01 · FY2008 · CA · contact PI
A Novel MAPK family in T. gondii$271,608
R01 · FY2008 · AI · contact PI
SAN ANTONIO CANCER INSTITUTE$2,737,958
P30 · FY2007 · CA · contact PI
PHASE II TRIAL OF ONTAK TO TREAT OVARIAN CANCER UNDER B*$350,000
R01 · FY2007 · FD · contact PI
CXCR4/SDF-1 interactions in ovarian cancer pathogenesis$283,792
R01 · FY2007 · CA · contact PI
A Novel MAPK family in T. gondii$276,869
R01 · FY2007 · AI · contact PI
Plasmacytoid dendritic cell behavior in ovarian cancer$273,408
R01 · FY2007 · CA · contact PI
SAN ANTONIO CANCER INSTITUTE$123,370
P30 · FY2007 · CA · contact PI
SAN ANTONIO CANCER INSTITUTE$3,069,362
P30 · FY2006 · CA · contact PI
PHASE II TRIAL OF ONTAK TO TREAT OVARIAN CANCER UNDER B*$350,000
R01 · FY2006 · FD · contact PI
A Novel MAPK family in T. gondii$302,064
R01 · FY2006 · AI · contact PI
CXCR4/SDF-1 interactions in ovarian cancer pathogenesis$297,272
R01 · FY2006 · CA · contact PI
Plasmacytoid dendritic cell behavior in ovarian cancer$286,396
R01 · FY2006 · CA · contact PI
CXCR4/SDF-1 interactions in ovarian cancer pathogenesis$189,271
R01 · FY2006 · CA · contact PI
Plasmacytoid dendritic cell behavior in ovarian cancer$151,981
R01 · FY2006 · CA · contact PI
A Novel MAPK family in T. gondii$61,405
R01 · FY2006 · AI · contact PI
DENDRITIC CELL-MEDIATED ANTI-TUMOR IMMUNITY$30,971
P51 · FY2006 · RR · contact PI
A PHASE II TRIAL OF INTRAVENOUS ONTAK TO TREAT EPITHELIAL OVARIAN CANCER FIGO$3,108
M01 · FY2006 · RR · contact PI
PHASE I/II DOSE DE-ESCALATION TRIAL OF INTRAVENOUS ONTAK IN PATIENTS WITH CANCER$972
M01 · FY2006 · RR · contact PI
SAN ANTONIO CANCER INSTITUTE$3,069,362
P30 · FY2005 · CA
CXCR4/SDF-1 interactions in ovarian cancer pathogenesis$304,425
R01 · FY2005 · CA
A Novel MAPK family in T. gondii$297,000
R01 · FY2005 · AI
Plasmacytoid dendritic cell behavior in ovarian cancer$293,288
R01 · FY2005 · CA
TARGETING SIV NEF DIRECTLY TO DENDRITIC CELLS$54,500
P51 · FY2005 · RR
DENDRITIC CELL-MEDIATED ANTI-TUMOR IMMUNITY$37,662
P51 · FY2005 · RR
PHASE I/II DOSE DE-ESCALATION TRIAL OF INTRAVENOUS ONTAK IN PATIENTS WITH CANCER$3,698
M01 · FY2005 · RR
CXCR4/SDF-1 interactions in ovarian cancer pathogenesis$304,425
R01 · FY2004 · CA
DENDRITIC CELL-MEDIATED ANTI-TUMOR IMMUNITY$46,011
P51 · FY2004 · RR
Phase I/II Dose De-Escalation Trial of Intravenous Ontak in Patients With Cancer$1,767
M01 · FY2004 · RR
Dendritic cell targeted hepatitis c virus immunotherapy$148,500
R21 · FY2003 · DA
DENDRITIC CELL-MEDIATED ANTI-TUMOR IMMUNITY$53,199
P51 · FY2003 · RR
DC-INDUCED HIV-SPECIFIC T CELL IMMUNITY$129,270
R21 · FY2001 · AI
DC-INDUCED HIV-SPECIFIC T CELL IMMUNITY$116,424
R21 · FY2001 · AI
DC-INDUCED HIV-SPECIFIC T CELL IMMUNITY$257,957
R21 · FY2000 · AI